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Abstract
Equine inÁ uenza virus is a leading cause of respiratory disease in horses worldwide. 
Disease prevention is by vaccination with inactivated whole virus vaccines. Most current 
inÁ uenza vaccines are generated in embryonated hens’ eggs. Virions are harvested from 
allantoic Á uid and chemically inactivated.  Although this system has served well over the 
years, the use of eggs as the substrate for vaccine production has several well-recognized 
disadvantages (cost, egg supply, waste disposal and yield in eggs). The aim of this study 
was to evaluate a baculovirus system as a potential method for producing recombinant 
equine inÁ uenza hemagglutinin to be used as a vaccine. The hemagglutinin ectodomain 
(HA1 subunit) was cloned and expressed using a baculovirus expression vector. The 
expression was determined by SDS-PAGE and immunoblotting. A high yield, 20 μg/ml of 
viral protein, was obtained from recombinant baculovirus-infected cells. The immune 
response in BALB/c mice was examined following rHA1 inoculation. Preliminary results 
show that recombinant hemagglutinin expressed from baculovirus elicits a strong 
antibody response in mice; therefore it could be used as an antigen for subunit vaccines 
and diagnostic tests.
© 2013 Asociación Argentina de Microbiología. Published by Elsevier España, S.L. All 
rights reserved.
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Introduction
Equine InÁ uenza is a disease that affects horses, donkeys 
and mules, which is currently considered one of the main 
causes of equine respiratory diseases around the world. Its 
causative agent is a virus belonging to the Orthomyxoviri-
dae family. Conventional equine inÁ uenza vaccines contain 
inactivated whole viruses either as an aqueous suspension 
or combined with adjuvants such as aluminum hydroxide or 
aluminum phosphate. For vaccine production, the inÁ uenza 
virus is usually grown in the amniotic cavity of fertile hens’ 
eggs or in a cell culture maintained in medium containing 
trypsin. Virions are harvested from egg allantoic Á uid or 
culture medium and are inactivated or treated with deter-
gent. A basic disadvantage these systems present is their 
variability and the heterogeneity of their cellular consti-
tuents9,13. Therefore, other methods for equine inÁ uenza 
vaccine production were developed. These include a ca-
narypox-vectored vaccine (ProteqFlu, Merial Inc., USA), a 
subunit vaccine containing puriÀ ed hemagglutinin and neu-
raminidase proteins adjuvated with ISCOMatrix (Equilis Pre-
quenza), an attenuated live vaccine (Flu Avert™ I.N., Inter-
vet) and many inactivated inÁ uenza vaccines, with the 
latter being the most widely used commercially. Vaccina-
tion against equine inÁ uenza has been recently reviewed12. 
During 2008, Protein Sciences Corporation reported the de-
velopment of a human inÁ uenza vaccine, named FluBlok®, 
using the insect cell/baculovirus technology. This vaccine 
was shown to be safe and efÀ cacious in clinical trials3,4,15. 
Insect cell systems have been widely used to produce re-
combinant proteins. The high yield obtained by baculovirus-
infected insect cells makes them attractive tools for phar-
maceutical protein production6.
Hemagglutinin is the dominant glycoprotein on the surfa-
ce of the inÁ uenza virus and a recognized key antigen in the 
host response to inÁ uenza virus in both natural infection 
and vaccination17. The protein, encoded by segment 4 of 
the viral genome, is initially translated as a preprotein 
(HA0) that is then split into two subunits (HA1 and HA2), 
which subsequently assemble to form a trimeric structure 
(HA1-HA2). In the spatial conformation that the mature he-
magglutinin takes, only the HA1 subunit becomes exposed 
and it is, therefore, where most of its antigenic determi-
nants are found16.
The present study was aimed at evaluating a baculovirus 
expression system as a potential method for producing re-
combinant equine inÁ uenza hemagglutinin.
Materials and methods
Virus and cells
An Argentine equine inÁ uenza virus strain previously isola-
ted in our laboratory, sharing high homology to strain A/
equine/Argentina/1999 (H3N8)  (more than 99%) and clo-
sely related to Floride clade 1 strains, was propagated in 
the allantoic cavity of 11 day-old embryonated hen’s eggs.
Spodoptera frugiperda (Sf9 and Sf21) cells (Gibco, Grand 
Island, NY, USA), used for the transfection and propagation 
of recombinant viruses, were cultured at 27 ºC in TC-100 
media (US Biological, Swampscott, MA, USA) supplemented 
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with 10% Fetal Bovine Serum (FBS) (PAA Laboratories GmbH, 
Pasching, Austria).
For the expression of recombinant HA1 subunit, Sf9, Sf21 
cells and Trichoplusia ni High Five cells (Invitrogen, Carls-
bad, CA, USA) were used. Three different culture media 
were tested: Grace’s (Gibco), TC-100 and SF900II (Gibco).
AmpliÀ cation by RT-PCR
Total RNA was extracted using Trizol reagent (Invitrogen). 
The reverse transcription was carried out using 1 μg of total 
RNA, the HA1R primer: 5´ CACTCGAGTTGCTTTTCTGG-
TACATTCCTC 3´ and Moloney Murine Leukemia Virus Rever-
se Transcriptase (Promega, Madison,WI, USA) under condi-
tions speciÀ ed by the supplier. The PCR reaction was 
performed by adding 5 μl from the cDNA to a reaction mix-
ture containing a À nal concentration of 200 μM of each one 
of the dNTPs, 1.5 mM of MgCl2, 0.25 U of Taq DNA polyme-
rase (Fermentas Inc, Glen Burnie, MD, USA) and 10 pmol of 
each one of primers: HA1R and HA1F: 5´ TACCATGGTCTA-
CAGTCAAAACCCAACCAG 3´. The ampliÀ cation was perfor-
med on a Mastercycler gradient (Eppendorf, Hamburg, Ger-
many). After denaturation at 94°C for 2 m, the reactions 
were cycled 30 times at 94°C for 30 s, 63°C for 30 s and 72°C 
1 m. This was followed by a À nal elongation step at 72°C for 
10 m. The PCR product was run on  1.5% agarose gel dyed 
with ethidium bromide.
Construction of a baculovirus transfer vector
The PCR-ampliÀ ed HA1 segment was ligated to a pCR2.1TOPO 
vector (Invitrogen) and transformed into One Shot TOP10 
Competent Cells (Invitrogen). Recombinant clones contai-
ning the insert were examined to ensure proper orientation 
by endonuclease restriction with XhoI (Promega) and DNA 
sequence analysis (Biotechnology Resource Center – Cornell 
University – Ithaca – New York, USA). For sub cloning, the 
HA1 coding sequence was digested with NcoI and BamHI 
(Promega). The resulting plasmid named pFastBac-HA was 
used to generate a recombinant baculovirus.
Generation of a recombinant baculovirus
In order to induce transposition between the recombinant 
transfer vector and Autographa californica nuclear polyhe-
drosis virus bacmid (bAcNPV), the pFastBac-HA vector was 
transformed into Eschericia coli DH10Bac (Invitrogen). After 
incubation, white recombinant and blue non-recombinant 
colonies could be clearly differentiated. To conÀ rm the 
transposition of the HA1 segment into the bAcNPV,  12 whi-
te colonies and one blue colony were analyzed for Colony-
PCR with M13 universal primers according to the protocol 
included in the Bac to Bac kit manual (Invitrogen).
The recombinant bacmid DNA extracted from previously 
tested white colonies was used to transfect Sf21 cells by 
using Insect GeneJuice® Transfection Reagent (Novagen, 
Madison, WI, USA). The transfected cells were cultured at 
27°C in TC-100 media supplemented with 10% fetal bovine 
serum. A primary virus stock was collected at 96 h post-
transfection and used to perform another two rounds of in-
fections. At 72 h of the second infection, the culture me-
dium supernatant was stored at —70°C to be used as viral 
stock in future protein expression assays.
Expression of recombinant proteins
High-titre recombinant baculovirus stock was used to in-
fect three insect cell lines (Sf9, Sf21 and High Five). Cell 
growth proÀ le was carried out at 27°C in 25 cm2 cell cultu-
re Á asks (Greiner Bio-one, Frickenhausen, Germany) with 
three different media: TC-100 and Grace’s supplemented 
with 10%  FBS and SF-900 II with and without FBS. Cells 
were infected during the mid-exponential growth phase, 
using a multiplicity of infection (MOI) of 0.25. A prelimi-
nary comparison of protein yields obtained with the three 
media was conducted by sampling 100 μl of culture super-
natants at different post-infection times. Supernatants 
from each cell line were collected daily during 4 days and 
recombinant HA1 production was analyzed by Polyacryla-
mide Gel Electrophoresis (SDS-PAGE). The proteins were 
separated by standard nonreduced SDS-PAGE on a 5% stac-
king gel and 12.5% polyacrylamide gel for 3.5 h at 60 V. 
The gels were stained with 0.1% Coomassie Brilliant Blue 
R250 (Sigma).
PuriÀ cation of the HA1 protein
A high-yield, homogenous preparation of HA1 subunit was 
obtained by using the nickel-nitrilotriacetic acid (Ni-NTA) 
resin (Qiagen, Hilden, Germany), according to standard 
procedures. In brief, after À nding the optimal expression 
conditions (see Results) a new culture at larger volume 
(25 ml of culture medium with 106 cells/ml) was made in 
175 cm2 cell culture Á asks (CellStar – Greiner). Three days 
post-infection, cells were harvested and washed three 
times with sterile PBS. The whole pellet of cells was 
disrupted by sonication with Binding Buffer (50 mM NaH2PO4, 
500 mM NaCl, pH 8.0).
The cell lysate was pelleted at 5000 g per 10 m and the 
total protein solution present in the supernatant (20 ml) 
was loaded into a Ni-NTA column pre-equilibrated with Bin-
ding Buffer. The bound protein was washed with buffer 
50mM NaH2PO4, 500mM NaCl, 20 mM Imidazole, pH 8.0 until 
the absorbance at an OD of 280 nm returned to baseline. 
Once the baseline was stable, elution of the bound recom-
binant protein was carried out using 20 ml of 50 mM 
NaH2PO4, 500 mM NaCl, 250 mM Imidazole (Merck), pH 8.0. 
The eluted recombinant protein was concentrated by preci-
pitation with absolute etanol and resuspended in 10 ml of 
sterile PBS.
Immunization of mice with HA1 protein
Sixteen 6 week- old female BALB/c mice were randomized 
into four groups. All animal procedures were performed 
conforming to approved protocols and in accordance with 
recommendations for the proper use and care of laboratory 
animals. Group I was intranasally (i.n.) inoculated with 1μg 
of puriÀ ed protein (quantiÀ ed by the Bradford assay). Group 
II was inoculated intramuscularly (i.m.) with a mixture of 
25 μl of HA1 protein solution (500 ng of puriÀ ed protein) 
and 25 μl of Specol adjuvant (ID-DLO, Lelystad, The Nether-
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lands). Group III was inoculated i.m. with 50 μl of HA1 pro-
tein solution (1 μg of puriÀ ed protein). Group IV was used as 
non-immunized control (Wable 1). Two booster immuniza-
tions were performed 15 and 30 days post-priming in iden-
tical conditions, but without adjuvant in the Group II. 
Serum samples of each group were collected and pooled 
before each inoculation and analyzed by Haemaglutination 
inhibition test (HI). Fifteenth days after the last immuniza-
tion all mice were sacriÀ ced and the level of anti-HA1 anti-
bodies was estimated by Western blot (WB) and HI from the 
pooled and individual samples respectively. The puriÀ ed vi-
rus obtained from allantoic Á uid of 11 day-old embryonated 
hen’s eggs was used as antigen.
Hemagglutination inhibition test
HI test was performed in V-bottomed microtitre plates with 
4 hemagglutinating units (HAU) of Equine InÁ uenza virus 
(H3N8) antigen and 0.5% of chicken red blood cells accor-
ding to standard procedures. Differences in log-transformed 
data from HI titers between the experimental groups were 
assessed using analysis of variance (ANOVA) followed by 
Tukey’s post-hoc test. The level of statistical signiÀ cance 
was set at P Value < 0.05.
Immunoblot analysis
Recombinant and viral proteins separated by SDS-PAGE 
were electrotransferred to a 0.22 μm pore size Nitrocellu-
lose membrane (Sigma) by using a semi-dry transfer blotter 
(BioRAD, Hercules, CA, USA) at 150 mA for 30 m. The mem-
brane was blocked overnight at 4 °C in PBS containing 5% 
skim milk and 0.1% Tween-20, then was reacted with 1:100 
dilution of each pool of sera. After 1.5 h, the membrane 
was washed three times with washing buffer (PBS contai-
ning 0.1% Tween-20) and subsequently incubated with hor-
seradish peroxidase (HRP) conjugated rabbit anti-mouse 
IgG (Sigma) at a 1:1000 dilution for 1.5 h at room tempera-
ture. After a last washing step, the membrane was develo-
ped in PBS with 0.05% diaminobenzidine tetrahydrochloride 
(Wako pure) in the presence of H2O2.
Results
Construction of the baculovirus transfer vector
RT-PCR ampliÀ cation assay using HA1F and HA1R primers 
generated a unique fragment having the expected molecu-
lar size (1002 bp) visible on agarose gel.
After cloning the PCR product into the pCR2.1-TOPO vec-
tor and transformation in TOP10 bacteria, more than 
100 clones were obtained. Twelve of them, randomly selec-
ted, were examined to ensure proper orientation by endo-
nuclease restriction with XhoI. One clone in the correct 
orientation was chosen for sequence analysis. Sequencing 
analysis conÀ rmed the correct open reading frame of the 
cloned segment. Finally, the HA1 fragment was digested 
with NcoI and BamHI enzymes and ligated into the pFastBac 
HTb vector to generate the plasmid pFastBac-HA.
Generation of the recombinant baculovirus
Recombinant baculoviruses were obtained by transforma-
tion of pFastBac-HA into E. coli DH10Bac. After one and a 
half days of incubation in Luria broth plates, several colo-
nies were observed. Twelve white colonies and one blue 
colony (non-recombinant) used as a negative control were 
analyzed by Colony-PCR with M13 universal primers. The 
transposition of the HA1 segment into the bAcNPV vector 
was conÀ rmed in eleven of the apparently positive colonies 
analyzed.
Four days after Sf21 cell transfection, decrease of cell 
growth, enlargement in cell diameter and detachment of 
cells from the monolayer were observed. Signs of cell infec-
tion were verify 72 h after re-infection of new Sf21.
Expression of the recombinant HA1 protein
After infection of Sf9, Sf21 and High Five cells, a recombi-
nant protein with a molecular weight of about 40 kDa was 
detected by SDS-PAGE. The size of the recombinant protein 
was approximated to the predicted molecular weight of the 
HA1 containing the N terminal His tag and was also compa-
rable to the size of the authentic viral HA1 subunit.
Analysis of cell lysate and cell culture media showed that 
the maximum expression of recombinant protein was achie-
ved at 96 hours post-infection of High Five cells grown in 
TC-100 media supplemented with 10% of FBS (Iig. 1). No 
signiÀ cant expression levels were detected with Sf-9 cells 
or Sf-21 cells during the 96-hour analysis (data not shown).
PuriÀ cation of the HA1 protein
Recombinant HA1 protein was puriÀ ed to near homogeneity 
by Immobilized Metal-ion AfÀ nity Chromatography (IMAC) 
with NTA-Ni2+ resin (QIAGEN). Protein purity was analysed 
and conÀ rmed by SDS-PAGE (Iig. 2). Protein concentration 
was determined by the standard Bradford assay. After puri-
À cation,  a À nal concentration of 20 μg/ml of protein was 
obtained.
The presence of a single band on polyacrylamide gel 
(Fig. 2) suggested that the protein was puriÀ ed by IMAC al-
most to homogeneity and the amount of protein quantiÀ ed 
by the Bradford assay method corresponded completely to 
the recombinant HA1 protein.
Table 1 Inoculation chart
Group Inoculation 
viaa
Protein 
volumeb
Specol 
volume
Inoculated 
volume
I i.n. 50 μl - 50 μl
II i.m. 25 μl 25 μlc 50 μl
III i.m. 50 μl - 50 μl
IV unvaccinated control group
a i.n.: intranasal; i.m.: intramuscular.
b Protein solution concentration: 20 ng/μl.
c Only in the À rst immunization.
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Hemagglutination inhibition test
For the statistical analysis of HI results (Wable 2), a logarith-
mic transformation of data was initially performed. No sig-
niÀ cant differences were found between the standard de-
viations of each group by using the Levene’s test with a 
conÀ dence level of 95.0% (P> 0, 42). The data were analy-
zed by one-way Analysis of Variance (ANOVA), demonstra-
ting signiÀ cant differences between groups of inoculated 
animals (Wable 3).
To determine which groups were signiÀ cantly different, a 
Tukey’s test was conducted. It showed that there were sig-
niÀ cant differences between Group II (animals inoculated 
intramuscularly with adjuvant) and other groups. Further-
more, signiÀ cant differences between Group III (IM) and 
Group IV (not inoculated control) were found, but no obser-
vable differences were noted between Group I (IN) and con-
trol. These results were subsequently conÀ rmed qualitati-
vely by western blot analysis using a pool of sera from each 
group (Iig. 3).
Discussion
The manufacture of current equine inÁ uenza vaccines in-
volves the use of several batches of antigen, virus strains, 
cell lines, etc. that may produce differences in the quality 
of the immunoreactive proteins included in the vaccine. Li-
censed egg-grown vaccines and many cell culture-derived 
vaccines need bio containment facilities or harsh chemicals 
such as formaldehyde in the manufacturing process. The 
main problems for preparation of these vaccines are the 
large amount of embryonated eggs needed and the failure 
to obtain high yields of virus8. On average, the yield of total 
viral protein from the embryonated eggs is approximately 
20-40 mg per 200 eggs5. Therefore, large scale production 
of inactivated vaccines is relatively difÀ cult and expensive.
Figure 1 SDS-PAGE analysis expressed recombinant protein. 
Lanes 1 to 5: cell lysates at 12, 24, 48, 72 and 96 hours post-
infection; lane 6: non-infected High Five cells control; lane 7: 
molecular weight marker (Fermentas).
Figure 2 SDS-PAGE analysis of the puriÀ ed recombinant HA1 
protein. Lane 1: molecular weight marker (Fermentas); lane 2: 
puriÀ ed recombinant protein by Ni2+ afÀ nity. 
Table 2 HI titer by group
Group
I II III IV
Mouse 1 4 64 4 2
Mouse 2 8 64 16 4
Mouse 3 4 128 16 2
Mouse 4 4 64 8 2
Figure 3 Western blot analysis of sera pools. Lane M, PageRu-
ler prestained marker (Fermentas); lane I, Group I (intranasal); 
lane II, Group II (animals inoculated intramuscularly with adju-
vant); lane III Group III (animals inoculated intramuscularly wi-
thout adjuvant) and lane IV, Group IV (not inoculated control).
Table 3 One-way ANOVA: Natural log of HI titer versus 
groups
Source DFa SSb MSc Fd Pe
Group 3 26.905 8.968 44.800 8.6x10—7
Error 12 2.402 0.200
Total 15 29.308
a degrees of freedom; b sum of squares; c mean square; 
d variance ratio; e probability.
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The major advantage of the baculovirus expression sys-
tem is that large amounts of recombinant proteins can be 
produced. Previous works have reported high yields of vi-
ral proteins by using baculovirus- insect cells systems. 
Nwe et al. obtained 77 μg/106 cells of recombinant HA1 
protein monolayer culture insect cells10, while Sugiura ob-
tained 0.4–4 μg/larvae of puriÀ ed hemagglutinin protein 
from silkworm larvae infected with recombinant baculovi-
rus14. In this study 20 μg/ml (corresponding to 200 μg of 
puriÀ ed HA1 from 2.5x107 cells) were obtained from re-
combinant baculovirus infected cells. Since glycosylation 
may play an important role in the biological function of 
HA18-20, it is of interest to know whether the rHA produced 
in insect cells is properly glycosylated. During the current 
experiment we did not analyze the HA1 glycosylation pat-
tern but Wang et al. have demonstrated that when a bacu-
lovirus expression system was used, all the N-linked oligo-
saccharide chains were present in the HA1 region indicating 
that the rHA produced in insect cells was indeed glycosyla-
ted with N-linked oligosaccharide side chains21. Our preli-
minary analysis in immunized mice indicated that the HA1 
recombinant protein retained its antigenicity. In this stu-
dy, Specol was used as an adjuvant. Specol was described 
by Bokhout et al.2. It is composed by a non-metabolisable 
mineral oil (Marcol 52) and two emulsiÀ ers. Typically, Spe-
col mainly induced antibodies of the IgG1 isotype1. Pre-
vious study in mice7 concluded that Specol might be an 
acceptable alternative to Freund’s complete adjuvant 
(FCA). Specol is generally regarded as safe for use in ani-
mals1,2, showing fewer adverse effects than other water-
oil adjuvants like  FCA and had demonstrated strong immu-
nostimulating properties. The use of Specol as an adjuvant 
signiÀ cantly enhanced the immune response of immunized 
mice, since when administrating approximately 500 ng of 
the protein with the adjuvant (Group II) the HI titre obtai-
ned was greater than that obtained by inoculation of 1 μg 
of protein in aqueous solution (Group III). On the other 
hand, no detectable levels of antibodies were found by HI 
or Western blot in serum samples from animals inoculated 
intranasally (Group I) (Fig. 3). Previous studies reported 
that intranasal administration of 1.5 μg of the HA recom-
binant baculovirus vaccine induced virus-speciÀ c antibo-
dies, as measured by enzyme-linked immunosorbent assay 
(ELISA), but did not induce virus neutralizing (VN) antibo-
dies11. This suggests that factors involving effectiveness of 
vaccination, such as route of administration, amount of 
inoculated protein, etc, may have a deep effect on the 
efÀ cacy of a subunit vaccine. Taken together, the above 
results indicate that the HA1 subunit, expressed in insect 
cells as N-terminus fusion proteins with a His-Tag sequen-
ce can be produced in large quantities in a biochemically 
active form from a small culture volume. The protein can 
be easily puriÀ ed, eliminating possible adverse reactions 
because it does not contain egg ovoalbumin. Moreover, vi-
rus inactivation or organic extraction procedures will not 
be necessary, thus avoiding possible denaturing effects 
and additional safety concerns due to residual toxic che-
micals in the vaccine. Incorporating recombinant techno-
logy for the production of an equine inÁ uenza vaccine 
might contribute to circumvent the disadvantages of the 
current egg-based production method. 
Although more studies are needed to assess the feasibili-
ty of the HA1 recombinant protein for vaccine production, 
our results demonstrate the usefulness of vaccination with 
an HA1 subunit in combination with an adjuvant as an 
approach to enhance antigen-speciÀ c immune response. 
Nevertheless, a suitable noninÁ ammatory adsorptive adju-
vant such as aluminum hydroxide or carbomer polymer may 
also be evaluated in future studies to determine the best 
formulation and inoculation route in horses.
The baculovirus system might be easily adapted to large 
scale manufacturing of different HA antigens, allowing for 
the development of equine inÁ uenza subunit vaccines and 
diagnostic tests and becoming a good alternative to the cu-
rrent egg-based inactivated vaccines. 
Ethical disclosures   
Protection of human and animal subjects. The authors de-
clare that the procedures followed were in accordance with 
the regulations of the responsible Clinical Research Ethics 
Committee and in accordance with those of the World Me-
dical Association and the Helsinki Declaration. 
ConÀ dentiality of Data. The authors declare that no pa-
tient data appears in this article 
Right to privacy and informed consent. The authors decla-
re that no patient data appears in this article. 
ConÁ icts of interest
The authors declare that they have no conÁ icts of interest.
Acknowledgements
This research was partially supported by Department of 
Science and Technology of National University of La Plata. 
N.A.F. hold fellowships of the Argentine Council for Scienti-
À c and Technical Research (CONICET). C.M.G. is Career Re-
searcher of CIC-PBA. 
References
1.  Boersma WJ, Bogaerts WJ, Bianchi AT, Claassen E. Adjuvant 
properties of stable water-in-oil emulsions: evaluation of the 
experience with Specol. Res Immunol. 1992;143:503-12.
2.  Bokhout BA, van Gaalen C, van der Heijden P. A selected water-
in-oil emulsion: composition and usefulness as an immunological 
adjuvant. Vet Immunol Immunopathol. 1981;2:491-500.
3.  Cox MM, Hollister JR. FluBlok®, a next generation inÁ uenza 
vaccine manufactured in insect cells. Biologicals. 2009;37:182-9.
4.  Huber VC, McCullers JA, FluBlok®, a recombinant inÁ uenza 
vaccine. Curr Opin Mol Ther. 2008;10:75-85.
5.  Johansson BE, Bucher DJ, Kilbourne ED. PuriÀ ed inÁ uenza virus 
hemagglutinin and neuraminidase are equivalent in stimulation 
of antibody response but induce contrasting types of immunity 
to infection. J Virol. 1989;63:1239-46.
6.  Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors 
for protein expression in insect and mammalian cells. Nat 
Biotechnol. 2005;23:567-75.
228 G.H. Sguazza et al 
7.  Leenaars PP, Hendriksen CF, Koedam MA, Claassen I, Claassen 
E. Comparison of adjuvants for immune potentiating properties 
and side effects in mice. Vet Immunol Immunopathol. 
1995;48:123-38.
8.  Lipatov AS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, Guan Y, 
Poon L, Webster RG. InÁ uenza: emergence and control. J Virol. 
2004;78:8951-9.
9.  Minke JM, Audonnet JC, Fischer L. Equine viral vaccines: the 
past, present and future. Vet Res. 2004;35:425-43.
10.  Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, 
Limlamthong Y, Fenner, BJ, Spencer L, Kwang J. Expression of 
hemagglutinin protein from the avian inÁ uenza virus H5N1 in a 
baculovirus/insect cell system signiÀ cantly enhanced by 
suspension culture. BMC Microbiol. 2006;24:6-16. 
11.  Olsen CW.,   McGregor MW., Dybdahl-Sissoko N.,  Schramt BR., 
Nelson KM. D.,  Lunn P.,  Macklin MD., Swaint WF., Hinshaw VS. 
Immunogenicity and efÀ cacy of baculovirus-expressed and 
DNA-based equine inÁ uenza virus hemagglutinin vaccines in 
mice. Vaccine, 1997;15:1149-56. 
12.  Paillot R, Hannant D, Kydd JH, Daly JM, Vaccination against 
equine inÁ uenza: Quid novi?. Vaccine. 2006;24:4047-61.
13.  Park AW, Wood JL, Newton JR, Daly J, Mumford JA, Grenfell BT. 
Optimising vaccination strategies in equine inÁ uenza. Vaccine. 
2003;21:2862-70.
14.  Sugiura T, Sugita S, Imagawa H, Kanaya T, Ishiyama S, Saeki N, 
Uchiyama A, Tanigawa M, Kuwano A Serological diagnosis of 
equine inÁ uenza using the hemagglutinin protein produced in 
a baculovirus expression system. J Virol Methods. 2001;98:
1-8.
15.  Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer 
AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M. Safety and 
immunogenicity of a baculovirus-expressed hemagglutinin 
inÁ uenza vaccine: a randomized controlled trial. JAMA. 
2007;297:1577-82.
16.  Wiley DC, Skehel JJ. The structure and function of the 
hemagglutinin membrane glycoprotein of inÁ uenza virus. Annu 
Rev Biochem. 1987;56:365-94.
17.  Yates P, Mumford JA. Equine inÁ uenza vaccine efÀ cacy: the 
signiÀ cance of antigenic variation. Vet Microbiol. 2000;74:
173-7.
18.  Klenk HD, Wagner R, Heuer D, Wolff T. Importance of 
hemagglutinin glycosylation for the biological functions 
of inÁ uenza virus.Virus Res 2002;82:73-5.
19.  Schulze IT. Effects of glycosylation on the properties and 
functions of inÁ uenza virus hemagglutinin. J Infect Dis. 
1997;176(Suppl.1):S24-8.
20.  Helenius A, Aebi M. Roles of N-linked glycans in the endoplasmic 
reticulum. Annu Rev Biochem. 2004;73:1019–49.
21.  Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox 
MMJ. Expression and puriÀ cation of an inÁ uenza hemagglutinin 
- one step closer to a recombinant protein-based inÁ uenza 
vaccine. Vaccine. 2006;24:2176-85.
